The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue‐type plasminogen activator
Plasminogen activators (tPA and uPA) are serine proteases that convert the circulating zymogen plasminogen to active plasmin and mediate fibrin degradation. These multifunctional proteins trigger various biological events such as extracellular matrix degradation, cell adhesion, migration, and prolif...
Gespeichert in:
Veröffentlicht in: | The FASEB journal 2004-09, Vol.18 (12), p.1398-1400 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1400 |
---|---|
container_issue | 12 |
container_start_page | 1398 |
container_title | The FASEB journal |
container_volume | 18 |
creator | Maupas‐Schwalm, Françoise Augé, Nathalie Robinet, Catherine Cambus, Jean‐Pierre Parsons, Sarah J. Salvayre, Robert Nègre‐Salvayre, Anne |
description | Plasminogen activators (tPA and uPA) are serine proteases that convert the circulating zymogen plasminogen to active plasmin and mediate fibrin degradation. These multifunctional proteins trigger various biological events such as extracellular matrix degradation, cell adhesion, migration, and proliferation, through not yet fully characterized mechanisms. We report that, in smooth muscle cells and ECV‐304 carcinoma cells, tPA and ATF (the N‐terminal catalytically inactive fragment of tPA) elicited DNA synthesis that requires activation of the sphingomyelin/ceramide/sphingosine‐1‐phosphate (Spm/Cer/S1P), signaling pathway and was blocked by D‐erythro‐2‐(N‐myristoylamino)‐1‐phenyl‐propanol (D‐MAPP) and N‐N’‐dimethyl sphingosine (DMS), two classical inhibitors of sphingosine‐1‐phosphate biosynthesis. Binding of tPA to its receptor uPAR triggered the coordinated activation of two key enzymes of the Spm/Cer/S1P pathway, the neutral sphingomyelinase and the sphingosine kinase‐1 that was mediated by a common pertussis toxin (PTX)‐sensitive mechanism. The tPA‐induced sphingosine kinase‐1 activation was mediated by Src, since it was inhibited by herbimycin A and in SrcK‐cells (overexpressing a dominant negative kinase defective form of Src) and by ERK1/2 (early phase peaking at 15 min). Sphingosine kinase‐1 activation was followed by a second phase of ERK1/2 phosphorylation (peaking at 120 min) and subsequent DNA synthesis, which were inhibited by D‐MAPP and DMS, by anti‐EGD‐1 antibodies and in SrcK‐cells (in which the mitogenic signaling was rescued by sphingosine‐1‐phosphate). Altogether, these data underline a pivotal role for the Spm/Cer/S1P pathway in the tPA‐induced mitogenic signaling. |
doi_str_mv | 10.1096/fj.03-1123fje |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66822120</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66822120</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406E-5e77344c75c997435727a9188206553e614c801cf6f66069a740cc896513f68a3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EokvhyBX5xIl0x3biJNxKtVsolUClnCPXGXe9cuJgJ1ty4xH6EDwZT4JXuxI3Th7b33yj0U_IawZnDGq5NNszEBljXJgtPiELVgjIZCXhKVlAVfNMSlGdkBcxbgGAAZPPyQkruGAlzxfk9-0GaRw2tr_33YzO9kuNQXW2RTqocfOgZmojtf3Oux22qaCrm89syemw8anPh9mp0fr-HdXoHB2Cd9Ykw-FN9S2dvp7fUL_DgD-HgDGmj6RpJ510dzMdbYwT_vn1OM5DmulU7Gzv77GnSo92p0YfXpJnRrmIr47nKfm-Xt1efMyuv1x-uji_znQOcpUVWJYiz3VZ6Louc1GUvFQ1qyoOsigESpbrCpg20kgJslZlDlpXtSyYMLJS4pS8PXjTFj8mjGPT2bhfS_Xop9hIWXHOOCQwO4A6-BgDmmYItlNhbhg0-1gas21ANMdYEv_mKJ7uOmz_0cccEvD-ADxYh_P_bc362we-vgKxv6-vVuIvFfaeWg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66822120</pqid></control><display><type>article</type><title>The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue‐type plasminogen activator</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Maupas‐Schwalm, Françoise ; Augé, Nathalie ; Robinet, Catherine ; Cambus, Jean‐Pierre ; Parsons, Sarah J. ; Salvayre, Robert ; Nègre‐Salvayre, Anne</creator><creatorcontrib>Maupas‐Schwalm, Françoise ; Augé, Nathalie ; Robinet, Catherine ; Cambus, Jean‐Pierre ; Parsons, Sarah J. ; Salvayre, Robert ; Nègre‐Salvayre, Anne</creatorcontrib><description>Plasminogen activators (tPA and uPA) are serine proteases that convert the circulating zymogen plasminogen to active plasmin and mediate fibrin degradation. These multifunctional proteins trigger various biological events such as extracellular matrix degradation, cell adhesion, migration, and proliferation, through not yet fully characterized mechanisms. We report that, in smooth muscle cells and ECV‐304 carcinoma cells, tPA and ATF (the N‐terminal catalytically inactive fragment of tPA) elicited DNA synthesis that requires activation of the sphingomyelin/ceramide/sphingosine‐1‐phosphate (Spm/Cer/S1P), signaling pathway and was blocked by D‐erythro‐2‐(N‐myristoylamino)‐1‐phenyl‐propanol (D‐MAPP) and N‐N’‐dimethyl sphingosine (DMS), two classical inhibitors of sphingosine‐1‐phosphate biosynthesis. Binding of tPA to its receptor uPAR triggered the coordinated activation of two key enzymes of the Spm/Cer/S1P pathway, the neutral sphingomyelinase and the sphingosine kinase‐1 that was mediated by a common pertussis toxin (PTX)‐sensitive mechanism. The tPA‐induced sphingosine kinase‐1 activation was mediated by Src, since it was inhibited by herbimycin A and in SrcK‐cells (overexpressing a dominant negative kinase defective form of Src) and by ERK1/2 (early phase peaking at 15 min). Sphingosine kinase‐1 activation was followed by a second phase of ERK1/2 phosphorylation (peaking at 120 min) and subsequent DNA synthesis, which were inhibited by D‐MAPP and DMS, by anti‐EGD‐1 antibodies and in SrcK‐cells (in which the mitogenic signaling was rescued by sphingosine‐1‐phosphate). Altogether, these data underline a pivotal role for the Spm/Cer/S1P pathway in the tPA‐induced mitogenic signaling.</description><identifier>ISSN: 0892-6638</identifier><identifier>EISSN: 1530-6860</identifier><identifier>DOI: 10.1096/fj.03-1123fje</identifier><identifier>PMID: 15231724</identifier><language>eng</language><publisher>United States: Federation of American Societies for Experimental Biology</publisher><subject>Benzoquinones ; Cell Line ; Cell Proliferation - drug effects ; Ceramides - metabolism ; Enzyme Activation - drug effects ; Extracellular Signal-Regulated MAP Kinases - metabolism ; Lactams, Macrocyclic ; Lysophospholipids - pharmacology ; MAP Kinase Signaling System - drug effects ; Mitogens - pharmacology ; Myocytes, Smooth Muscle - cytology ; Myocytes, Smooth Muscle - drug effects ; Myocytes, Smooth Muscle - enzymology ; Myocytes, Smooth Muscle - metabolism ; Peptide Fragments - chemistry ; Peptide Fragments - pharmacology ; Pertussis Toxin - pharmacology ; Phosphorylation - drug effects ; Phosphotransferases (Alcohol Group Acceptor) - metabolism ; Quinones - pharmacology ; Rifabutin - analogs & derivatives ; Signal Transduction - drug effects ; Sphingomyelins - metabolism ; Sphingosine - analogs & derivatives ; Sphingosine - pharmacology ; sphingosine kinase ; Src ; Tissue Plasminogen Activator - pharmacology ; tPA ; Up-Regulation - drug effects ; Urokinase-Type Plasminogen Activator - chemistry ; Urokinase-Type Plasminogen Activator - genetics ; Urokinase-Type Plasminogen Activator - pharmacology</subject><ispartof>The FASEB journal, 2004-09, Vol.18 (12), p.1398-1400</ispartof><rights>FASEB</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406E-5e77344c75c997435727a9188206553e614c801cf6f66069a740cc896513f68a3</citedby><cites>FETCH-LOGICAL-c406E-5e77344c75c997435727a9188206553e614c801cf6f66069a740cc896513f68a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1096%2Ffj.03-1123fje$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1096%2Ffj.03-1123fje$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27931,27932,45581,45582</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15231724$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maupas‐Schwalm, Françoise</creatorcontrib><creatorcontrib>Augé, Nathalie</creatorcontrib><creatorcontrib>Robinet, Catherine</creatorcontrib><creatorcontrib>Cambus, Jean‐Pierre</creatorcontrib><creatorcontrib>Parsons, Sarah J.</creatorcontrib><creatorcontrib>Salvayre, Robert</creatorcontrib><creatorcontrib>Nègre‐Salvayre, Anne</creatorcontrib><title>The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue‐type plasminogen activator</title><title>The FASEB journal</title><addtitle>FASEB J</addtitle><description>Plasminogen activators (tPA and uPA) are serine proteases that convert the circulating zymogen plasminogen to active plasmin and mediate fibrin degradation. These multifunctional proteins trigger various biological events such as extracellular matrix degradation, cell adhesion, migration, and proliferation, through not yet fully characterized mechanisms. We report that, in smooth muscle cells and ECV‐304 carcinoma cells, tPA and ATF (the N‐terminal catalytically inactive fragment of tPA) elicited DNA synthesis that requires activation of the sphingomyelin/ceramide/sphingosine‐1‐phosphate (Spm/Cer/S1P), signaling pathway and was blocked by D‐erythro‐2‐(N‐myristoylamino)‐1‐phenyl‐propanol (D‐MAPP) and N‐N’‐dimethyl sphingosine (DMS), two classical inhibitors of sphingosine‐1‐phosphate biosynthesis. Binding of tPA to its receptor uPAR triggered the coordinated activation of two key enzymes of the Spm/Cer/S1P pathway, the neutral sphingomyelinase and the sphingosine kinase‐1 that was mediated by a common pertussis toxin (PTX)‐sensitive mechanism. The tPA‐induced sphingosine kinase‐1 activation was mediated by Src, since it was inhibited by herbimycin A and in SrcK‐cells (overexpressing a dominant negative kinase defective form of Src) and by ERK1/2 (early phase peaking at 15 min). Sphingosine kinase‐1 activation was followed by a second phase of ERK1/2 phosphorylation (peaking at 120 min) and subsequent DNA synthesis, which were inhibited by D‐MAPP and DMS, by anti‐EGD‐1 antibodies and in SrcK‐cells (in which the mitogenic signaling was rescued by sphingosine‐1‐phosphate). Altogether, these data underline a pivotal role for the Spm/Cer/S1P pathway in the tPA‐induced mitogenic signaling.</description><subject>Benzoquinones</subject><subject>Cell Line</subject><subject>Cell Proliferation - drug effects</subject><subject>Ceramides - metabolism</subject><subject>Enzyme Activation - drug effects</subject><subject>Extracellular Signal-Regulated MAP Kinases - metabolism</subject><subject>Lactams, Macrocyclic</subject><subject>Lysophospholipids - pharmacology</subject><subject>MAP Kinase Signaling System - drug effects</subject><subject>Mitogens - pharmacology</subject><subject>Myocytes, Smooth Muscle - cytology</subject><subject>Myocytes, Smooth Muscle - drug effects</subject><subject>Myocytes, Smooth Muscle - enzymology</subject><subject>Myocytes, Smooth Muscle - metabolism</subject><subject>Peptide Fragments - chemistry</subject><subject>Peptide Fragments - pharmacology</subject><subject>Pertussis Toxin - pharmacology</subject><subject>Phosphorylation - drug effects</subject><subject>Phosphotransferases (Alcohol Group Acceptor) - metabolism</subject><subject>Quinones - pharmacology</subject><subject>Rifabutin - analogs & derivatives</subject><subject>Signal Transduction - drug effects</subject><subject>Sphingomyelins - metabolism</subject><subject>Sphingosine - analogs & derivatives</subject><subject>Sphingosine - pharmacology</subject><subject>sphingosine kinase</subject><subject>Src</subject><subject>Tissue Plasminogen Activator - pharmacology</subject><subject>tPA</subject><subject>Up-Regulation - drug effects</subject><subject>Urokinase-Type Plasminogen Activator - chemistry</subject><subject>Urokinase-Type Plasminogen Activator - genetics</subject><subject>Urokinase-Type Plasminogen Activator - pharmacology</subject><issn>0892-6638</issn><issn>1530-6860</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhi0EokvhyBX5xIl0x3biJNxKtVsolUClnCPXGXe9cuJgJ1ty4xH6EDwZT4JXuxI3Th7b33yj0U_IawZnDGq5NNszEBljXJgtPiELVgjIZCXhKVlAVfNMSlGdkBcxbgGAAZPPyQkruGAlzxfk9-0GaRw2tr_33YzO9kuNQXW2RTqocfOgZmojtf3Oux22qaCrm89syemw8anPh9mp0fr-HdXoHB2Cd9Ykw-FN9S2dvp7fUL_DgD-HgDGmj6RpJ510dzMdbYwT_vn1OM5DmulU7Gzv77GnSo92p0YfXpJnRrmIr47nKfm-Xt1efMyuv1x-uji_znQOcpUVWJYiz3VZ6Louc1GUvFQ1qyoOsigESpbrCpg20kgJslZlDlpXtSyYMLJS4pS8PXjTFj8mjGPT2bhfS_Xop9hIWXHOOCQwO4A6-BgDmmYItlNhbhg0-1gas21ANMdYEv_mKJ7uOmz_0cccEvD-ADxYh_P_bc362we-vgKxv6-vVuIvFfaeWg</recordid><startdate>200409</startdate><enddate>200409</enddate><creator>Maupas‐Schwalm, Françoise</creator><creator>Augé, Nathalie</creator><creator>Robinet, Catherine</creator><creator>Cambus, Jean‐Pierre</creator><creator>Parsons, Sarah J.</creator><creator>Salvayre, Robert</creator><creator>Nègre‐Salvayre, Anne</creator><general>Federation of American Societies for Experimental Biology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200409</creationdate><title>The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue‐type plasminogen activator</title><author>Maupas‐Schwalm, Françoise ; Augé, Nathalie ; Robinet, Catherine ; Cambus, Jean‐Pierre ; Parsons, Sarah J. ; Salvayre, Robert ; Nègre‐Salvayre, Anne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406E-5e77344c75c997435727a9188206553e614c801cf6f66069a740cc896513f68a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Benzoquinones</topic><topic>Cell Line</topic><topic>Cell Proliferation - drug effects</topic><topic>Ceramides - metabolism</topic><topic>Enzyme Activation - drug effects</topic><topic>Extracellular Signal-Regulated MAP Kinases - metabolism</topic><topic>Lactams, Macrocyclic</topic><topic>Lysophospholipids - pharmacology</topic><topic>MAP Kinase Signaling System - drug effects</topic><topic>Mitogens - pharmacology</topic><topic>Myocytes, Smooth Muscle - cytology</topic><topic>Myocytes, Smooth Muscle - drug effects</topic><topic>Myocytes, Smooth Muscle - enzymology</topic><topic>Myocytes, Smooth Muscle - metabolism</topic><topic>Peptide Fragments - chemistry</topic><topic>Peptide Fragments - pharmacology</topic><topic>Pertussis Toxin - pharmacology</topic><topic>Phosphorylation - drug effects</topic><topic>Phosphotransferases (Alcohol Group Acceptor) - metabolism</topic><topic>Quinones - pharmacology</topic><topic>Rifabutin - analogs & derivatives</topic><topic>Signal Transduction - drug effects</topic><topic>Sphingomyelins - metabolism</topic><topic>Sphingosine - analogs & derivatives</topic><topic>Sphingosine - pharmacology</topic><topic>sphingosine kinase</topic><topic>Src</topic><topic>Tissue Plasminogen Activator - pharmacology</topic><topic>tPA</topic><topic>Up-Regulation - drug effects</topic><topic>Urokinase-Type Plasminogen Activator - chemistry</topic><topic>Urokinase-Type Plasminogen Activator - genetics</topic><topic>Urokinase-Type Plasminogen Activator - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maupas‐Schwalm, Françoise</creatorcontrib><creatorcontrib>Augé, Nathalie</creatorcontrib><creatorcontrib>Robinet, Catherine</creatorcontrib><creatorcontrib>Cambus, Jean‐Pierre</creatorcontrib><creatorcontrib>Parsons, Sarah J.</creatorcontrib><creatorcontrib>Salvayre, Robert</creatorcontrib><creatorcontrib>Nègre‐Salvayre, Anne</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The FASEB journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maupas‐Schwalm, Françoise</au><au>Augé, Nathalie</au><au>Robinet, Catherine</au><au>Cambus, Jean‐Pierre</au><au>Parsons, Sarah J.</au><au>Salvayre, Robert</au><au>Nègre‐Salvayre, Anne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue‐type plasminogen activator</atitle><jtitle>The FASEB journal</jtitle><addtitle>FASEB J</addtitle><date>2004-09</date><risdate>2004</risdate><volume>18</volume><issue>12</issue><spage>1398</spage><epage>1400</epage><pages>1398-1400</pages><issn>0892-6638</issn><eissn>1530-6860</eissn><abstract>Plasminogen activators (tPA and uPA) are serine proteases that convert the circulating zymogen plasminogen to active plasmin and mediate fibrin degradation. These multifunctional proteins trigger various biological events such as extracellular matrix degradation, cell adhesion, migration, and proliferation, through not yet fully characterized mechanisms. We report that, in smooth muscle cells and ECV‐304 carcinoma cells, tPA and ATF (the N‐terminal catalytically inactive fragment of tPA) elicited DNA synthesis that requires activation of the sphingomyelin/ceramide/sphingosine‐1‐phosphate (Spm/Cer/S1P), signaling pathway and was blocked by D‐erythro‐2‐(N‐myristoylamino)‐1‐phenyl‐propanol (D‐MAPP) and N‐N’‐dimethyl sphingosine (DMS), two classical inhibitors of sphingosine‐1‐phosphate biosynthesis. Binding of tPA to its receptor uPAR triggered the coordinated activation of two key enzymes of the Spm/Cer/S1P pathway, the neutral sphingomyelinase and the sphingosine kinase‐1 that was mediated by a common pertussis toxin (PTX)‐sensitive mechanism. The tPA‐induced sphingosine kinase‐1 activation was mediated by Src, since it was inhibited by herbimycin A and in SrcK‐cells (overexpressing a dominant negative kinase defective form of Src) and by ERK1/2 (early phase peaking at 15 min). Sphingosine kinase‐1 activation was followed by a second phase of ERK1/2 phosphorylation (peaking at 120 min) and subsequent DNA synthesis, which were inhibited by D‐MAPP and DMS, by anti‐EGD‐1 antibodies and in SrcK‐cells (in which the mitogenic signaling was rescued by sphingosine‐1‐phosphate). Altogether, these data underline a pivotal role for the Spm/Cer/S1P pathway in the tPA‐induced mitogenic signaling.</abstract><cop>United States</cop><pub>Federation of American Societies for Experimental Biology</pub><pmid>15231724</pmid><doi>10.1096/fj.03-1123fje</doi><tpages>20</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0892-6638 |
ispartof | The FASEB journal, 2004-09, Vol.18 (12), p.1398-1400 |
issn | 0892-6638 1530-6860 |
language | eng |
recordid | cdi_proquest_miscellaneous_66822120 |
source | MEDLINE; Access via Wiley Online Library; Alma/SFX Local Collection |
subjects | Benzoquinones Cell Line Cell Proliferation - drug effects Ceramides - metabolism Enzyme Activation - drug effects Extracellular Signal-Regulated MAP Kinases - metabolism Lactams, Macrocyclic Lysophospholipids - pharmacology MAP Kinase Signaling System - drug effects Mitogens - pharmacology Myocytes, Smooth Muscle - cytology Myocytes, Smooth Muscle - drug effects Myocytes, Smooth Muscle - enzymology Myocytes, Smooth Muscle - metabolism Peptide Fragments - chemistry Peptide Fragments - pharmacology Pertussis Toxin - pharmacology Phosphorylation - drug effects Phosphotransferases (Alcohol Group Acceptor) - metabolism Quinones - pharmacology Rifabutin - analogs & derivatives Signal Transduction - drug effects Sphingomyelins - metabolism Sphingosine - analogs & derivatives Sphingosine - pharmacology sphingosine kinase Src Tissue Plasminogen Activator - pharmacology tPA Up-Regulation - drug effects Urokinase-Type Plasminogen Activator - chemistry Urokinase-Type Plasminogen Activator - genetics Urokinase-Type Plasminogen Activator - pharmacology |
title | The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue‐type plasminogen activator |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T18%3A40%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20sphingomyelin/ceramide%20pathway%20is%20involved%20in%20ERK1/2%20phosphorylation,%20cell%20proliferation,%20and%20uPAR%20overexpression%20induced%20by%20tissue%E2%80%90type%20plasminogen%20activator&rft.jtitle=The%20FASEB%20journal&rft.au=Maupas%E2%80%90Schwalm,%20Fran%C3%A7oise&rft.date=2004-09&rft.volume=18&rft.issue=12&rft.spage=1398&rft.epage=1400&rft.pages=1398-1400&rft.issn=0892-6638&rft.eissn=1530-6860&rft_id=info:doi/10.1096/fj.03-1123fje&rft_dat=%3Cproquest_cross%3E66822120%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66822120&rft_id=info:pmid/15231724&rfr_iscdi=true |